抄録
Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95% confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95% CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 539-546 |
| ページ数 | 8 |
| ジャーナル | Oncology reports |
| 巻 | 33 |
| 発行部数 | 2 |
| DOI | |
| 出版物ステータス | 出版済み - 12 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
これを引用
Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer. / Nagayoshi, Kinuko; Ueki, Takashi; Tashiro, Kosuke; Mizuuchi, Yusuke; Manabe, Tatsuya; Araki, Hiromitsu; Oda, Yoshinao; Kuhara, Satoru; Tanaka, Masao.
：: Oncology reports, 巻 33, 番号 2, 01.12.2015, p. 539-546.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer
AU - Nagayoshi, Kinuko
AU - Ueki, Takashi
AU - Tashiro, Kosuke
AU - Mizuuchi, Yusuke
AU - Manabe, Tatsuya
AU - Araki, Hiromitsu
AU - Oda, Yoshinao
AU - Kuhara, Satoru
AU - Tanaka, Masao
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95% confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95% CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.
AB - Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95% confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95% CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.
UR - http://www.scopus.com/inward/record.url?scp=84919444079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919444079&partnerID=8YFLogxK
U2 - 10.3892/or.2014.3660
DO - 10.3892/or.2014.3660
M3 - Article
C2 - 25504183
AN - SCOPUS:84919444079
VL - 33
SP - 539
EP - 546
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 2
ER -